Autoresearch: WuXi 1260H DoD answer is due September 18, not September 1

Generated by in-vault research on 2026-09-02 (headless daily, ~05:00 ET). Step 1 refresh of biosecure-cdmo-scarcity-to-western-cdmo-pricing-power / WuXi 1260H, plus step 2 buckets #8 healthcare & demographics and #9 financials & the rate regime. Treat as raw material. Priors skipped (headless).

Summary

Yesterday's dispatch treated September 1 as the day the Defense Department had to answer WuXi AppTec's 1260H complaint. The docket already moved. On August 27, 2026, Chief Judge James E. Boasberg granted a second consent extension: defendants "shall file their Answer or otherwise respond to Plaintiff's Complaint by September 18, 2026" (CourtListener docket, 1:26-cv-02069). The August 7 preliminary injunction still bars DoD from giving effect to the designation. OMB's BCOC list remains December 18, 2026. Still no 2026 realized CDMO price series. This is a calendar correction, not a chain flip. Do not silently downgrade biosecure-cdmo-scarcity-to-western-cdmo-pricing-power. Human call on the −15% fill-finish contradiction is now day fourteen, with a dated next gate.

Findings

WuXi / 1260H (the day's actual news)

From the CourtListener docket:

• August 11: first consent extension → answer due September 1.
• August 27 minute order: second consent extension granted. Answer or other response due September 18, 2026.
• August 7 order (unchanged): preliminary injunction granted; DoD enjoined from enforcing, implementing, or otherwise giving effect to the 1260H designation; $1 bond.

The September 1 "due today, none found" pass in 2026-09-01-autoresearch-truckload-supply-tightening-not-demand was looking at a deadline that had already been moved. No answer appeared because the court had given DoD seventeen more days. The injunction is the live constraint; the answer is a filing, not a designation.

Still no 2026 realized Western CDMO price series. The −15% mAb fill-finish contradiction is not resolved by a docket extension. Human call. Do not invent a hypothesis page that decides it.

FERC / PJM ER26-3380 (also-checked)

Still no Commission order as of this run. PJM's July 31 Reliability Backstop filing still asks FERC to accept by September 29 so the central bid window can open September 30–October 21, results by December 2. A September calendar note: the RBP target-adjustment window is September 10–October 9 (last chance for a zone to reflect a completed bilateral before central targets are set) (Verse, PJM September turning point; Power Magazine on IRAS). IRAS requested effective date remains October 12. Do not re-rate CEG on silence. Next gate unchanged: September 29.

Intel 18A / 14A (also-checked)

Still no named outside 18A/14A high-volume order. TrendForce's September 1 recap of CFO Zinsner at the Deutsche Bank conference: 14A defect-reduction trajectory "fastest since 22nm"; external talks have moved from data-review toward capacity questions; 14A PDK 0.9 still October; risk production H2 2027 / HVM 2028 (TrendForce, 2026-09-01). Defect curve ≠ purchase order. October PDK 0.9 remains the dated test. intel-18a-yield-vs-tsmc stays open.

ACA / hospitals / insurers (bucket #8)

Enhanced PTCs expired January 1, 2026. House three-year extension passed in January; Senate CARE Act talks remain stalled. No September floor action found this pass. The Senate's dated September item is the CLARITY Act cloture on September 15, not CARE (HTX / cloture calendar). aca-subsidy-extension-outcome-to-insurer-direction stays a policy-headline watch. OSCR / CNC / MOH not graduated.

Hospital-operator evidence from July–August Q2 calls (HCA CEO Hazen: ACA-loss patients going uninsured "almost one for one"; HCA uncompensated care +29% YoY) already sits on aca-subsidy-cliff-to-deferred-procedure-volume. No new September print. Do not re-file Q2 as if it were new.

Financials / Warsh (bucket #9)

FOMC September 15–16 is still the next rate meeting. Warsh's Jackson Hole keynote (August 28) refused a reaction function; that is already on warsh-higher-for-longer-to-brokerage-nii-rerate. No new Chair print overnight. Schwab Q2 NII sensitivity (~$250–300M annualized per 25 bp) is the existing call. Do not graduate SCHW. The September 15–16 statement is still the conversion test.

What this does to the chains

• biosecure-cdmo-scarcity-to-western-cdmo-pricing-power: calendar correction only. Injunction holds. Next docket gate September 18. Conviction / status unchanged. Human call on the price-series contradiction continues.
• pjm-capacity-prices-to-nuclear-premium: silence. Next gate September 29. Do not re-rate CEG.
• intel-18a-yield-vs-tsmc: Zinsner 14A color is already the August conference tape, recapped September 1. Not a named order. Stays open.
• aca-subsidy-cliff-to-deferred-procedure-volume: no new legislative path. Hospital Q2 evidence already filed.
• warsh-higher-for-longer-to-brokerage-nii-rerate: still a hypothesis. FOMC September 15–16.

Contradictions and open questions

• The CDMO contradiction is now a dated miss of a deadline that had already moved. That does not make the −15% series go away. Fourteenth day. Flagged, not decided.
• If FERC issues a rejection of ER26-3380 before September 29, the September 30 window is the falsifier, not silence.
• If Zinsner or Tan names an outside 18A/14A HVM customer before PDK 0.9, the open question closes the other way.

Provenance

Method: in-vault WebSearch + WebFetch (headless daily; not a Grok Bot). No native X this pass. Fetched: CourtListener docket 1:26-cv-02069; Verse PJM September calendar. Search-only (not fetched): TrendForce Zinsner recap; Power Magazine IRAS; ASTHO / NPR ACA history; Healthcare Dive HCA Q2 (already in wiki); Schwab Q2 Fool transcript (already in wiki). Early exit: one-pass scoring of a docket primary + also-checked FERC / 18A / ACA / Warsh. No round 3. Priors: skipped (headless).